Pa Chengzhou, Shen Shijun, Dai Yunrui, Wu Min
Department of Hepatobiliary Pancreatic and Vascular Surgery, First People's Hospital of Kunming, The Affiliated Calmette Hospital of Kunming Medical University, Kunming, China.
Department of Minimally Invasive Hepatobiliary and Pancreatic Surgery, Lincang People's Hospital, Lincang, China.
Front Hum Neurosci. 2025 Jun 18;19:1614132. doi: 10.3389/fnhum.2025.1614132. eCollection 2025.
Neurodegenerative diseases (NDs) are progressive disorders with an increasing global health impact. Neural injury biomarkers have emerged as potential tools for early diagnosis and disease monitoring.
To map research trends in this field, we conducted a comprehensive bibliometric analysis of 1,228 peer-reviewed articles published from 1991 to 2024 using CiteSpace and the Bibliometrix R package.
Our analysis revealed steady publication growth, particularly accelerating after 2015. The United States, United Kingdom, and China produced the highest volume of publications and citations, with institutions such as the University of California System and Harvard University serving as key collaboration hubs. Early research prioritized tau, amyloid-beta (Aβ), cerebrospinal fluid (CSF), and mild cognitive impairment (MCI). Since 2020, the focus has expanded to blood-based biomarkers, exosomal microRNAs, and inflammation-related markers such as glial fibrillary acidic protein (GFAP) and translocator protein (TSPO). Through citation and clustering analyses, we identified three developmental phases: (1) CSF-based amyloid/tau validation, (2) multimodal and genetic biomarker integration, and (3) the emergence of plasma and neuroinflammatory markers.
These trends reflect a paradigm shift toward minimally invasive and multifactorial diagnostic approaches. Our findings underscore evolving priorities in NDs biomarker research and highlight the importance of multi-omics, artificial intelligence (AI), and interdisciplinary collaboration for translational discovery and clinical application.
神经退行性疾病（NDs）是一类进行性疾病，对全球健康的影响日益增加。神经损伤生物标志物已成为早期诊断和疾病监测的潜在工具。
为了梳理该领域的研究趋势，我们使用CiteSpace和Bibliometrix R包对1991年至2024年发表的1228篇同行评审文章进行了全面的文献计量分析。
我们的分析显示出版物数量稳步增长，尤其是在2015年之后加速增长。美国、英国和中国的出版物和被引频次最高，加利福尼亚大学系统和哈佛大学等机构是关键的合作中心。早期研究优先关注tau蛋白、淀粉样β蛋白（Aβ）、脑脊液（CSF）和轻度认知障碍（MCI）。自2020年以来，研究重点已扩展到基于血液的生物标志物、外泌体微小RNA以及炎症相关标志物，如胶质纤维酸性蛋白（GFAP）和转位蛋白（TSPO）。通过引文分析和聚类分析，我们确定了三个发展阶段：（1）基于脑脊液的淀粉样蛋白/tau蛋白验证，（2）多模式和基因生物标志物整合，以及（3）血浆和神经炎症标志物的出现。
这些趋势反映了向微创和多因素诊断方法的范式转变。我们的研究结果强调了神经退行性疾病生物标志物研究中不断变化的重点，并突出了多组学、人工智能（AI）以及跨学科合作在转化发现和临床应用中的重要性。
